You are here

J&J to buy Actelion for US$30b and spin off Swiss drugmaker's R&D unit

World's largest maker of healthcare products pips Sanofi of France to the deal despite walking away earlier

actelion.jpg
Johnson & Johnson agreed to buy Actelion Ltd for US$30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines treating a rare type of high blood pressure.

New York

JOHNSON & JOHNSON agreed to buy Actelion Ltd for US$30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines treating a rare type of high blood pressure.

With the purchase, J&

sentifi.com

Market voices on:

Powered by GET.comGetCom